Apellis CSO granted 25,840 restricted stock units

Apellis Pharmaceuticals Chief Scientific Officer receives new equity grant.

Rhea-AI Filing Summary

Apellis Pharmaceuticals Chief Scientific Officer receives new equity grant. Pascal Deschatelets was awarded 25,840 shares of Apellis common stock on January 28, 2026 as a restricted stock unit grant at a price of $0 per share. These units vest 25% each year over four years, conditioned on continued service. Following this award, he beneficially owns 1,177,222 shares of Apellis common stock held directly.

Insider Trade Summary

Grant/Award: 25,840 shares

Grant/Award 1 txn

Insider Deschatelets Pascal

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	25,840	$0.00	$0.00

Holdings After Transaction: Common Stock — 1,177,222 shares (Direct)

Footnotes (1)

1. F1. This represents a Restricted Stock Unit award granted on January 28, 2026 that vest 25% annually over four years from grant date subject to continued service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Apellis (APLS) report for its Chief Scientific Officer?

Apellis reported that Chief Scientific Officer Pascal Deschatelets received 25,840 shares of common stock as a restricted stock unit grant. The award was made on January 28, 2026 at a price of $0 per share, increasing his direct beneficial ownership.

How many Apellis (APLS) shares does the Chief Scientific Officer own after this Form 4?

After the reported transaction, Chief Scientific Officer Pascal Deschatelets beneficially owns 1,177,222 shares of Apellis common stock. This total reflects his holdings following the grant of 25,840 restricted stock units reported in the Form 4 filing.

What are the vesting terms of the new Apellis (APLS) restricted stock unit grant?

The restricted stock unit award of 25,840 Apellis shares vests 25% annually over four years from the January 28, 2026 grant date. Vesting is subject to continued service, meaning the executive must remain with the company to receive each installment.

Was the Apellis (APLS) Form 4 transaction a purchase or a grant?

The Form 4 reports an award, not an open-market purchase. Chief Scientific Officer Pascal Deschatelets received 25,840 shares of Apellis common stock through a restricted stock unit grant at a price of $0 per share, classified with transaction code “A” for acquisition.

Is the Apellis (APLS) Chief Scientific Officer’s ownership direct or indirect?

The filing shows that the 1,177,222 Apellis common shares beneficially owned by Chief Scientific Officer Pascal Deschatelets are held as direct ownership. The transaction is coded with ownership form “D,” and no indirect holding entity is noted in the disclosure.

What does transaction code “A” mean in the Apellis (APLS) Form 4 filing?

In this Apellis Form 4, transaction code “A” denotes an acquisition of securities. Specifically, it reflects the grant of 25,840 restricted stock units of Apellis common stock to Chief Scientific Officer Pascal Deschatelets rather than a market purchase or sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/30/2026 - 04:10 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Deschatelets Pascal

(Last) (First) (Middle)

C/O APELLIS PHARMACEUTICALS, INC.

100 FIFTH AVENUE, 3RD FLOOR

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apellis Pharmaceuticals, Inc. [ APLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/28/2026		A		25,840(1)	A	$0	1,177,222	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This represents a Restricted Stock Unit award granted on January 28, 2026 that vest 25% annually over four years from grant date subject to continued service.

	/s/ David Watson, attorney-in-fact for Pascal Deschatelets	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.